Samsara Vision, Inc.
We are a specialty medical device company dedicated to bringing vision and freedom back to patients suffering from late-stage conditions of the retina. We are engaged in the research, development, manufacturing and marketing of proprietary ophthalmic devices and technologies that are intended to significantly improve the vision and quality of life of individuals with untreatable retinal disorders, particularly Age-Related Macular Degeneration (“AMD”). Our team is passionately developing a solution for patients in this underserved group. There are more than 11 million people living today with blindness from AMD. This group not only suffers from loss of vision, but also a significant loss of social function and the depression that goes along with it.
Our current product line consists of our first-generation implantable miniature telescope (“IMT”), which we refer to as WA IMT; our Smaller-Incision, New Generation (SING) IMT, which we refer to as SING IMT; and our Tsert delivery system. Our WA IMT is the first implantable medical device approved by the U.S. Food and Drug Administration (“FDA”) that works similarly to the telephoto lens of a camera, which enables improvement in vision and quality of life for individuals with the most advanced form of AMD, commonly referred to as late-stage AMD. It is important to note that not every patient with late-stage AMD is a candidate for treatment using our WA IMT.
Our WA IMT was approved by the FDA in July 2010 and received a Conformité Européenne Mark (“CE Mark”) in August 2005.
(Note: Samsara Vision, Inc. revived its recently postponed IPO with downsized terms in an S-1/A filing on March 10, 2022: 2.5 million shares, down from 4.17 million, at $5 to $7 to raise $15 million. On Thursday, Jan. 27, 2022, Samsara Vision postponed its IPO – just hours ahead of its expected pricing.)
|Industry:||Specialty Medical Device - Vision|
|Address||27 US HWY 202 (Ste 8/9) Far Hills, NJ 07931|
|Phone Number||(877) 997-4448|
|View Prospectus:||Samsara Vision, Inc.|
|Revenues||$39.0 mil (last 12 months)|
|Net Income||$-8.24 mil (last 12 months)|
|Price range||$5.00 - $7.00|
|Est. $ Volume||$15.0 mil|
|Manager / Joint Managers||ThinkEquity|
|Expected To Trade:||1/28/2022|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|